🚀𝐌𝐞𝐫𝐜𝐤’𝐬 𝐊𝐞𝐲𝐭𝐫𝐮𝐝𝐚 𝐧𝐚𝐛𝐬 𝐅𝐃𝐀 𝐧𝐨𝐝 𝐢𝐧 𝐛𝐢𝐥𝐢𝐚𝐫𝐲 𝐭𝐫𝐚𝐜𝐭 𝐜𝐚𝐧𝐜𝐞𝐫, 𝐜𝐚𝐭𝐜𝐡𝐢𝐧𝐠 𝐮𝐩 𝐰𝐢𝐭𝐡 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚’𝐬 𝐈𝐦𝐟𝐢𝐧𝐳𝐢💊 In November 2023, Merck Group KEYTRUDA® (pembrolizumab) HCP is on a winning streak scoring its sixth FDA (Food and Drug Administration) approval in #gastrointestinalcancers. The FDA (Food and Drug Administration) has based the approval on #data provided by company’s phase III keynote-966 trial that has shown its #Keytruda-chemo combo extended the #patients survival time as compared to the #chemotherapy. The Merck is proud to offer this #newtreatment option for biliary tract patients. 👉𝑹𝒆𝒍𝒂𝒕𝒆𝒅 𝑹𝒆𝒑𝒐𝒓𝒕:https://bit.ly/3tVa310 #Keytruda #Merck #AstraZeneca #Imfinzi #durvalumab #healthcare #prophecy #marketresearch #prophecymarketinsights
